anti-IL-23 aptamer

Band Therapeutics (also known as Guardian Therapeutics) is developing an IL-23-binding aptamer designed to inhibit Interleukin-23 (IL-23) signaling for the treatment of inflammatory and autoimmune disorders. The program is bifurcated into two distinct clinical focuses: a dermatology program utilizing a topical formulation for autoimmune skin diseases, and a gastroenterology program utilizing an oral formulation for Inflammatory Bowel Disease (IBD). By leveraging aptamer technology—synthetic oligonucleotide ligands—the drug aims to provide a targeted therapeutic approach to blocking the IL-23 pathway, which is a critical driver of chronic inflammation in both the skin and the gastrointestinal tract.

Other names

Anti-IL-23Anti-IL23Anti-IL 23IL-23-binding aptamerIL23-binding aptamerIL 23-binding aptamer